Evogene (EVGN) Competitors $1.25 -0.03 (-1.97%) Closing price 03:58 PM EasternExtended Trading$1.25 +0.00 (+0.32%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, SNES, TOMZ, BSLK, GURE, CNEY, NITO, ENFY, TANH, and GAMCWShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), Senestech (SNES), TOMI Environmental Solutions (TOMZ), Bolt Projects (BSLK), Gulf Resources (GURE), CN Energy Group. (CNEY), N2OFF (NITO), Enlightify (ENFY), Tantech (TANH), and Golden Arrow Merger (GAMCW). Evogene vs. Its Competitors Carisma Therapeutics Senestech TOMI Environmental Solutions Bolt Projects Gulf Resources CN Energy Group. N2OFF Enlightify Tantech Golden Arrow Merger Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk. Do analysts recommend EVGN or CARM? Evogene currently has a consensus target price of $3.50, indicating a potential upside of 181.12%. Carisma Therapeutics has a consensus target price of $1.93, indicating a potential upside of 5,173.97%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Carisma Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, EVGN or CARM? Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvogene$8.51M0.79-$16.49M-$2.25-0.55Carisma Therapeutics$10.77M0.14-$60.48M-$1.56-0.02 Do institutionals & insiders have more ownership in EVGN or CARM? 10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is EVGN or CARM more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Evogene-211.61% -109.96% -38.47% Carisma Therapeutics -254.28%N/A -192.17% Which has more risk & volatility, EVGN or CARM? Evogene has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Does the media prefer EVGN or CARM? In the previous week, Carisma Therapeutics had 1 more articles in the media than Evogene. MarketBeat recorded 1 mentions for Carisma Therapeutics and 0 mentions for Evogene. Evogene's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score. Company Overall Sentiment Evogene Neutral Carisma Therapeutics Neutral SummaryCarisma Therapeutics beats Evogene on 9 of the 15 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.69M$3.42B$6.17B$10.67BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-0.5523.2129.5928.52Price / Sales0.79477.49578.90129.07Price / CashN/A45.5937.1261.42Price / Book0.4510.3412.046.52Net Income-$16.49M-$52.53M$3.32B$276.75M7 Day Performance-2.73%-0.29%-0.17%0.21%1 Month Performance6.23%10.83%5.75%1.68%1 Year Performance-50.40%14.10%65.69%32.79% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.2885 of 5 stars$1.25-2.0%$3.50+181.1%-54.5%$6.69M$8.51M-0.55140Gap UpCARMCarisma Therapeutics2.5506 of 5 stars$0.04-19.5%$1.93+5,131.0%-96.4%$1.54M$19.63M-0.0220SNESSenestech1.9195 of 5 stars$3.98-3.2%$10.00+151.3%+32.0%$19.54M$1.86M-0.7330TOMZTOMI Environmental Solutions2.0186 of 5 stars$0.96-2.6%$3.50+266.5%+6.2%$19.18M$7.74M-4.1520Upcoming EarningsShort Interest ↑BSLKBolt Projects0.9856 of 5 stars$3.56-1.9%N/A-72.2%$13.29M$1.37M-1.3812Short Interest ↓GUREGulf Resources0.8283 of 5 stars$0.51-1.6%N/A-27.9%$6.75M$7.66M-0.20420News CoveragePositive NewsStock SplitShort Interest ↓CNEYCN Energy Group.1.1091 of 5 stars$2.12+1.2%N/A-87.9%$6.38M$50.96M0.00160News CoveragePositive NewsNITON2OFF0.5218 of 5 stars$4.41-0.2%N/A-60.9%$4.19M$210K0.002ENFYEnlightify1.1907 of 5 stars$0.10-72.8%N/AN/A$1.58M$95.85M-0.08424Short Interest ↓Gap DownHigh Trading VolumeTANHTantech0.3912 of 5 stars$1.73+0.9%N/A-82.3%$155K$42.94M0.0070Gap DownGAMCWGolden Arrow MergerN/A$0.04-1.6%N/AN/A$0.00N/A0.0012Gap Up Related Companies and Tools Related Companies CARM Competitors SNES Competitors TOMZ Competitors BSLK Competitors GURE Competitors CNEY Competitors NITO Competitors ENFY Competitors TANH Competitors GAMCW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVGN Stock Alerts